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Abstract
Objectives—Critical congenital heart disease (CCHD) was added recently to the U.S. 
Recommended Uniform Screening Panel for newborns. This study assessed whether maternal/
household and infant characteristics were associated with late CCHD detection.
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Methods—This was a state-wide, population-based, retrospective, observational study of infants 
with CCHD born 1998-2007 identified by the Florida Birth Defects Registry. We examined 12 
CCHD conditions that are primary and secondary targets of newborn CCHD screening by pulse 
oximetry. We used Poisson regression models to analyze associations between selected 
characteristics (e.g., maternal age, CCHD type, and birth hospital nursery level [highest level 
available in the hospital]) and late CCHD detection, which was defined as diagnosis after the birth 
hospitalization.
Results—Of 3,603 infants with CCHD and linked hospitalizations, CCHD was not detected 
during the birth hospitalization for 22.9% (n=825) of infants. The likelihood of late detection 
varied by CCHD condition. Infants born in a birth hospital with a Level I nursery only (adjusted 
prevalence ratio [aPR] 1.9, 95% confidence interval (CI) 1.6-2.2) or Level II nursery (aPR 1.5, 
95% CI 1.3-1.7) were significantly more likely to have late-detected CCHD compared to infants 
born in a birth hospital with a Level III (highest) nursery.
Conclusions—After controlling for the selected characteristics, hospital nursery level appears to 
have an independent association with late CCHD detection. Thus, perhaps universal newborn 
screening for CCHD could be particularly beneficial in Levels I and II nurseries and may reduce 
differences in the frequency of late diagnosis between birth hospital facilities.
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INTRODUCTION
Infants with critical congenital heart disease (CCHD) – heart defects requiring surgical or 
catheter intervention in the first year of life – are at risk for cardiovascular collapse or death 
if discharged from the birth hospital without a CCHD diagnosis.1 Pulse oximetry monitoring 
is the instrument currently used for CCHD screening. It is a non-invasive measurement of 
blood oxygen saturation that, in some cases, can detect CCHD in newborns whose condition 
was not detected prenatally or during routine postnatal examination.2 In light of recent 
clinical evidence of the benefits of pulse oximetry screening, CCHD was added to the U.S. 
Recommended Uniform Screening Panel for newborns in 2011.3
Few studies have investigated factors associated with late or missed detection of critical or 
other congenital heart disease (CHD). In a 1999 study using data from the Baltimore-
Washington Infant Study (BWIS), researchers found that among infants with CHD who died 
during the first year of life, factors associated with missed CHD diagnosis included the 
presence of multiple congenital malformations, low birth weight, prematurity, intrauterine 
growth restriction, and CHD type.4 The authors also found an association between missed 
diagnosis and low paternal education, but did not find a correlation with other paternal or 
maternal sociodemographic characteristics.4 In a study using California state-wide death 
registry data between 1998-2004, researchers estimated that 0.9 per 100,000 infants in 
California, extrapolated to approximately 36 infants in the United States, die annually due to 
missed CCHD diagnosis and the likelihood of death due to missed diagnosis varied by 
CCHD type.5
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In a 2013 study using data from the Florida Birth Defects Registry (FBDR), researchers 
found 22.9% of infants born 1998-2007 and ultimately diagnosed with CCHD did not 
receive a CCHD diagnosis during their birth hospitalization.6 Our objective was to use these 
same population-based data to examine whether selected characteristics were associated 
with late CCHD detection. In particular, we examined hospital nursery level of care because 
research suggests that tertiary level hospitals may detect fewer additional infants with 
CCHD through screening because of greater clinical awareness and use of prenatal diagnosis 
relative to community hospitals.7
METHODS
Study population
This was a state-wide, population-based, retrospective, observational study of infants with 
CCHD born January 1, 1998, through December 31, 2007, identified by the FBDR. The 
FBDR is a passive, state-wide, population-based surveillance system that identifies infants 
with birth defects, such as CCHD, from multiple databases of health care information.8-10 
Infants in the FBDR are ascertained during the first year of life, primarily using hospital 
discharge records from Florida’s Agency for Health Care Administration (AHCA).8-11 
AHCA does not collect information from non-hospital based birthing centers, though 
approximately 99% of births in Florida are in-hospital.12 The FBDR also includes 
information from state vital statistics, thereby capturing infant deaths that occur outside of 
the hospital setting. The FBDR does not capture information on adopted infants, prospective 
adoptees or on infants whose mothers delivered out-of-state.8-10,13
There were several inclusion criteria for this analysis. First, infants had an International 
Classification of Disease, 9th revision; Clinical Modification (ICD-9-CM) code in the 
FBDR for CCHD conditions considered as primary or secondary targets of newborn pulse 
oximetry screening. Primary targets include defects that always or most always present with 
hypoxemia: dextro-transposition of the great arteries [d-TGA], 745.10; truncus arteriosus 
[TA], 745.0; total anomalous pulmonary venous connection [TAPVC], 747.41; tricuspid 
atresia [TRA], 746.1; pulmonary atresia (with intact septum) [PA], 746.01; hypoplastic left 
heart syndrome [HLHS], 746.7; tetralogy of Fallot [TOF], 745.2.1,14,15 Secondary targets 
include defects that sometimes present with hypoxemia: double-outlet right ventricle 
[DORV], 745.11; Ebstein anomaly [EA], 746.2; coarctation/hypoplasia of aortic arch 
[COA], 747.10; aortic interruption/atresia/hypoplasia [AI/A], 747.11, 747.22; and single 
ventricle [SV], 745.3.1,14,15 Secondly, infants had a corresponding birth hospitalization 
discharge record from AHCA. Lastly, if there was no CCHD ICD-9-CM code on the birth 
hospitalization record, infants had at least one subsequent hospital admission or record of 
death due to any cause within the first year of life.
Variable construction
Our outcome of interest was late detection of CCHD compared to timely detection. Timely 
detection was defined as the presence of any CCHD ICD-9-CM diagnosis code on the birth 
hospital discharge record or, if applicable, on a subsequent hospitalization determined to be 
a transfer from the birth hospital. Hospitalizations were considered transfers if the 
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subsequent admission occurred on the same day as the birth hospital discharge or within one 
day of birth hospital discharge and an accompanying “transfer” admission code was present.
Selected maternal/household characteristics of interest were: age, race/ethnicity, nativity, 
education, expected principal healthcare payer status during the birth hospitalization, and 
birth hospital nursery level (I, III, or III [highest]).15 Principal healthcare payer status was 
defined as private insurance (i.e., employer-based insurance, including Tricare), public 
insurance (i.e., Medicare, Medicaid, Veteran’s Administration insurance, or other state/local 
government insurance in Florida), and self-pay/uninsured. The birth hospital nursery level 
was coded as the highest level in the facility (e.g., a hospital with Level II and III beds was 
classified as Level III). Infant characteristics of interest were: sex, preterm birth, presence of 
a non-cardiac congenital anomaly (i.e., major structural defects and selected genetic 
conditions), plurality, and specific CCHD condition.
Statistical analysis
Because late detection of CCHD was relatively common in our study population (i.e., 23% 
prevalence), we estimated the relative risk of late detection related to each characteristic of 
interest by comparing the prevalence of late detection at each exposure level. For each 
variable of interest, which was selected a priori, we estimated unadjusted and adjusted 
prevalence ratios and corresponding 95% confidence intervals in Poisson regression models 
with robust variance estimation.17
For multivariable analysis, we constructed two primary models: 1) effect of CCHD type for 
infants with a single CCHD condition, excluding infants with multiple CCHDs; and 2) effect 
of single CCHD versus multiple CCHDs among the entire study sample. All other variables 
of interest were included in both models. Although our main analyses included both primary 
and secondary CCHD screening targets, we also report separate analyses restricted to infants 
with the primary screening targets (i.e., d-TGA, TA, TAPVC, TRA, PA, HLHS, 
TOF).1,14,15 Finally, we conducted a separate analysis restricted to infants that did not 
experience a birth hospital transfer because infants who were transferred from their birth 
hospital may be different in terms of symptoms or severity than non-transferred infants. All 
models controlled for infants’ birth year with time dummy variables. All analyses were 
performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).
RESULTS
We identified 4,105 infants with ICD-9-CM codes indicating a CCHD in the FBDR and 
born 1998 - 2007, with an estimated birth prevalence of 19 per 10,000 live births 
(n=4,105/2,135,000).13 Among these infants, 3,655 had a birth hospitalization discharge 
record. Of these infants, 3,603 had a CCHD diagnosis on the birth hospitalization discharge 
record or at least one subsequent hospital discharge record or record of death and constituted 
the group of infants for analysis (Figure 1). Infants with CCHD in the FBDR that did not 
meet any of the inclusion criteria (n=502, 12.2%) were significantly more likely to have 
been born to mothers who were less educated, unmarried, foreign-born, and of Hispanic 
ethnicity than infants included in the analysis. Infants excluded from the analysis were more 
likely to be multiple births than infants included in the analysis. There were no significant 
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differences in maternal age, infant sex, birth year, or death during infancy between infants 
included and excluded from the analysis.
Among the 3,603 infants, 22.9% (n=825) of infants had late-detected CCHD (Table 1). 
Among infants with one of the seven primary CCHD screening targets (n=1,639, 45.5%), 
21.2% (n=348) had late-detected CCHD. The most common single CCHD condition among 
infants with timely detection was TOF (20.2%; n=561/2,778). The most common condition 
among infants with late-detected CCHD was COA (33.3%; n=275/825). Approximately 
20% (n=568/2,778) of timely-detected infants and 8.0% (n=66/825) of late-detected infants 
died during infancy. About 53% (n=1,462/2,778) of timely-detected infants and 10.3% 
(n=85/825) of late-detected infants were transferred to another hospital during the birth 
hospitalization.
In bivariate analyses, several characteristics were associated with late detection (Table 1). In 
comparison to mothers 25-34 years of age, infants born to younger mothers (≤ 24 years of 
age) were significantly more likely to be late-detected. Infants born to mothers with a high 
school education were more likely to be late-detected than infants whose mother attended 
college or university. The relative risk of late detection was greater among infants with U.S.-
born mothers than among those with foreign-born mothers. Premature infants were less 
likely than term infants to have late-detected CCHD.
In the multivariable model controlling for CCHD condition among infants with a single 
CCHD condition, among other factors, the birth hospital nursery level and infants’ CCHD 
condition were significantly associated with late detection (Table 2). The prevalence of late 
detection was significantly higher for birth years 2001 and 2004 than 2007. The relative risk 
of late detection was significantly greater among infants born in a Level I hospital nursery 
(adjusted prevalence ratio [aPR]: 1.9, 95% confidence interval [CI]: 1.6-2.2) or Level II 
hospital nursery (aPR: 1.5, 95% CI: 1.3-1.7) compared to infants born in a birth hospital 
with a Level III nursery. The magnitude and direction of these associations did not differ 
substantially in the model controlling for single versus multiple CCHD conditions (Level I 
nursery aPR: 2.1, 95% CI: 1.8-2.4; Level II nursery aPR: 1.5, 95% CI: 1.3-1.7). The results 
were similar when the analysis was restricted to infants with one of the primary CCHD 
screening targets (Level I nursery aPR: 1.9, 95% CI: 1.6-2.4; Level II nursery aPR: 1.3, 95% 
CI: 1.1-1.7) or when restricted to infants who did not experience birth hospital transfers 
(Level I nursery aPR: 2.3, 95% CI: 1.9-2.7; Level II nursery aPR: 1.8, 95% CI: 1.5-2.1).
Infants with AI/A, COA, DORV, PA, SV, TA, TAPVC, and TOF were significantly more 
likely to experience late detection compared to infants with HLHS (Table 2). Infants with 
multiple CCHD conditions were significantly less likely to be late-detected than infants with 
a single CCHD (aPR: 0.5, 95% CI: 0.4-0.6). In a model restricted to infants with the primary 
CCHD screening targets, the significance, direction, and magnitude of the association of PA, 
TA, TAPVR, and TOF and late detection remained similar (data not shown). Likewise, the 
results were similar when restricted to infants that did not experience birth hospital transfers 
(data not shown).
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Our results suggest that birth hospital nursery level and infants’ CCHD type are associated 
with late detection. Infants born in hospitals with only Level I or II nursery facilities were 
more likely to have late-detected CCHD compared to infants born in hospitals with Level III 
nursery facilities. From Table 1, it can be calculated that the rate of late detection was 37% 
for infants born in hospitals with Level I nurseries and 26% for infants born in hospitals with 
Level II nurseries – which suggests that infants born in hospitals with only Level I or II 
nurseries may be at substantial risk of leaving the birth hospital with an undiagnosed CCHD. 
One possible explanation for this association is the greater use of pulse oximetry and other 
diagnostic tools in higher level nurseries. However, routine pulse oximetry screening 
practices are focused on detecting CCHD conditions in asymptomatic newborns – newborns 
unlikely to be admitted to higher level nurseries prior to diagnosis. The birth cohort in our 
study predated the 2011 addition of screening for CCHD to the U.S. Recommended Uniform 
Screening Panel. In addition, although we do not have data on the use of pulse oximetry 
screening in Florida during our study period, a 2007 survey of pediatric cardiologists 
suggests a low utilization of routine pulse oximetry screening at that time.18 Another 
hypothesis is that hospitals with Level III nurseries may detect more cases of CCHD through 
prenatal diagnosis and clinical awareness relative to community hospitals;7 thus, the greatest 
benefit to newborn CCHD screening may accrue to infants born in community hospitals.
The prevalence of late detection varied by CCHD type. Although these conditions share the 
characteristic of requiring surgical or catheter intervention within the first year of life, they 
represent a heterogeneous grouping of conditions with varying pathology, clinical 
presentation and risk of hypoxemia during the birth hospitalization. This heterogeneity also 
has implications for routine pulse oximetry screening, with the sensitivity of screening likely 
variable by specific condition.19
Most of the characteristics that were significant in the bivariate analyses ceased to be 
significant in the multivariable models. Several maternal factors associated with late 
detection in the bivariate analysis were also associated with delivering in a hospital with a 
Level I nursery (e.g., younger maternal age, high school graduate or equivalent, and U.S.-
born) and having public insurance (e.g., younger maternal age, high school graduate), 
suggesting these factors are possibly related to access to higher-level hospital facilities.20 
The significance of preterm birth in the bivariate analyses also could have been related to 
hospital facility level because premature labor could lead mothers to give birth in facilities 
with more sophisticated nursery care and premature infants may be under increased 
scrutiny.21
This study was limited by several factors. First, the study could not control for the role of 
prenatal diagnosis in late detection because prenatal diagnosis information is not available in 
the FBDR. According to data provided by the Florida Department of Health’s Bureau of 
Community Health Assessment, the distribution of births by nursery level (defined as the 
highest nursery level available in the facility) was significantly different (p-value <0.001) 
for infants with CCHD (nursery Level I: 18.7%; Level II: 22.5%; Level III: 58.7%) 
compared to all infants born in the same Florida hospitals (nursery Level I: 19.6%; Level II: 
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31.1%; Level III: 49.3%). The increased frequency of delivery at hospitals with higher level 
nurseries could reflect mothers’ choices or clinical advice to attend such birth hospitals due 
to prenatal diagnosis of CCHD. In particular, prenatal diagnosis of CCHD might account for 
the gap in the frequency of late diagnosis between infants born at hospitals with Levels II 
and III nursery facilities. However, regardless of the explanation for the association, routine 
CCHD screening could reduce differences in the frequency of late diagnosis.
This study was limited also by its use of hospital-wide indicators of nursery level. It would 
have been preferable to examine the nursery in which an infant actually received care. 
Another limitation is that this study relied on administrative data based on ICD-9-CM codes, 
which are imperfect identifiers of CCHD conditions.22,23 Even though the FBDR uses 
multiple data sources to ascertain infants with birth defects, the diagnoses are not clinically 
verified. However, the FBDR’s overall completeness of ascertainment of birth defects has 
been estimated at approximately 87%, with case ascertainment variation noted by specific 
defect.9,10 A recent report on the prevalence of select CCHDs among birth defect 
surveillance programs in the United States showed that while individual programs’ birth 
defects prevalence estimates varied, partially due to differences in case finding, mean 
prevalence estimates across programs were similar for several CCHDs.24 Our dataset 
reflected information from one state, which limits generalizability. Lastly, we were unable to 
control for length of stay as a determinant of timely detection. An infant who is hospitalized 
longer is more likely to be detected with CCHD prior to discharge. However, because 
CCHD diagnosis also leads to longer length of stay, we could not use length of stay as an 
independent predictor. The shorter average length of stay in hospitals with Level I or II 
nurseries might help account for the greater frequencies of late-detected CCHD among 
infants in those hospitals.
The main study strengths lie in the setting and design. We used a state-wide, population-
based birth defects registry data over several years. This dataset included information on all 
state-based hospital admissions and ICD-9-CM codes for infants identified as having 
CCHD. These data are from a large and racially/ethnically diverse source population. In 
2010, Florida was the fourth most populous state and ranked fourth in annual number of live 
births in the United States.25 Florida was also third in annual live births to Hispanic women 
and first in annual live births to African-American women.25 Our results indicate that the 
study sample demographics are generally representative of the overall live-births in Florida, 
with the exception that infants with CCHD were more likely to have been born preterm, a 
common association with birth defects,26-28 and included 9% fewer Hispanic mothers than 
expected.13
CONCLUSION
This study assessed whether selected characteristics were associated with late CCHD 
detection among a population-based, state-wide cohort of infants with CCHD identified by a 
state birth defects registry. We found that infants born in hospitals with Level I and Level II 
nurseries were more likely to have a late diagnosis than infants born in hospitals with Level 
III nurseries. These results suggest that universal newborn screening for CCHD could be 
particularly beneficial for infants born in hospitals with Level I and II nurseries. 
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Implementing universal pulse oximetry screening in these nurseries may be challenging due 
to resource constraints. However, in a recent study in New Jersey, where screening is 
currently mandated, the nursing staff reported that pulse oximetry was a familiar skill and 
screening all newborns for CCHD was easily added to other routine tasks.29 The N.J. study 
and a second study in Georgia, where screening is voluntary, found that differences in 
screening practices between hospitals could be reduced with more staff education.29,30
This study highlights the importance and use of birth defects surveillance data, which, along 
with hospital discharge data, can help inform newborn screening programs and other 
decisions.31 Additional population-based studies with clinically verified CCHD conditions, 
information on prenatal diagnosis, and conducted after pulse oximetry screening 
implementation could confirm these findings. Such studies could link birth defects 
surveillance, medical records, hospital discharge, and insurance data as well as information 
from prenatal care facilities in various states.
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What’s Known on This Subject
Newborns with critical congenital heart disease are at risk of cardiovascular collapse or 
death if discharged from the birth hospital without a diagnosis. Newborn screening aims 
to identify critical congenital heart disease missed in prenatal and postnatal examinations.
What This Study Adds
Birth hospital nursery level and critical congenital heart disease type were found to be 
associated with late critical congenital heart disease detection. Routine newborn 
screening could conceivably reduce differences in the frequency of late diagnosis 
between birth hospital facilities.
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Infant data inclusion flowchart
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Table 1

















 ≤ 24 945 (34.0) 321 (38.9) 1.2 (1.0-1.3)
 25-34 1,338 (48.2) 376 (45.6) Reference
 ≥ 35 495 (17.8) 128 (15.5) 0.8 (0.7-1.0)
Mother’s race / ethnicity
 White, non-Hispanic 1,495 (53.9) 470 (57.0) Reference
 Black, non-Hispanic 621 (22.4) 178 (21.6) 1.0 (0.8-1.1)
 Hispanic 586 (21.1) 155 (18.8) 0.9 (0.8-1.1)
 Asian / Pacific Islander and American Indian /
 Alaskan 50 (1.8) 17 (2.1) 1.0 (0.6-1.5)
Mother’s education
 Less than high school graduate 564 (20.3) 177 (21.5) 1.1 (0.9-1.3)
 High school graduate or equivalent 912 (32.8) 304 (36.9) 1.2 (1.1-1.4)
 College or university (some or graduate) 1,275 (45.9) 340 (41.2) Reference
Mother’s nativity: foreign-born 677 (24.4) 163 (19.8) 0.8 (0.7-0.9)
Principal healthcare payer type on birth hospitalization
record
a
 Private 1,324 (47.7) 377 (45.7) Reference
 Public 1,360 (49.0) 409 (49.6) 1.1 (0.9-1.2)
 Self-Insured/Uninsured 94 (3.4) 39 (4.7) 1.3 (0.9-1.7)
Birth hospital nursery level
 I 425 (15.3) 250 (30.3) 2.1 (1.8-2.4)
 II 598 (21.5) 214 (25.9) 1.5 (1.3-1.8)
 III 1,755 (63.2) 361 (43.8) Reference
Infant
Sex, female 1,195 (43.0) 361 (43.8) 1.0 (0.9-1.2)
Preterm or very preterm birth (20-36 weeks) 595 (21.4) 143 (17.3) 0.8 (0.7-0.9)
Non-cardiac congenital anomaly 883 (31.8) 250 (30.3) 0.9 (0.8-1.1)
Plurality, multiple gestation 54 (1.9) 9 (1.1) 0.7 (0.4-1.3)
Critical congenital heart disease (CCHD) type
b,c
Single condition
 Hypoplastic left heart syndrome (HLHS)
c
196 (7.1) 27 (3.3) Reference
 Aortic interruption/atresia/hypoplasia (AI/A) 70 (2.5) 26 (3.2) 2.2 (1.4-3.6)
 Coarctation/hypoplasia of aortic arch (COA) 472 (17.0) 275 (33.3) 3.0 (2.1-4.4)



























 Double-outlet right ventricle (DORV) 77 (2.8) 32 (3.9) 2.4 (1.5-3.8)
 Dextro-transposition of the great arteries (d-TGA)
c
234 (8.4) 26 (3.2) 0.8 (0.5-1.4)
 Ebstein anomaly (EA) 76 (2.7) 11 (1.3) 1.0 (0.5-2.0)
 Pulmonary atresia (PA)
c
74 (2.7) 22 (2.7) 1.9 (1.1-3.2)
 Single ventricle (SV) 24 (0.9) 8 (1.0) 2.1 (1.0-4.1)
 Truncus arteriosus (TA)
c
69 (2.5) 32 (3.9) 2.6 (1.7-4.1)
 Total anomalous pulmonary venous connection
 (TAPVC)
c
55 (2.0) 37 (4.5) 3.3 (2.2-5.1)
 Tetralogy of Fallot (TOF)
c
561 (20.2) 184 (22.3) 2.0 (1.4-3.0)
 Tricuspid atresia (TRA)
c
102 (3.7) 20 (2.4) 1.4 (0.8-2.3)
Multiple conditions 768 (27.7) 125 (15.2) 0.5 (0.4-0.7)
Year of birth
 1998 247 (8.9) 73 (8.9) 1.1 (0.8-1.5)
 1999 234 (8.4) 86 (10.4) 1.3 (0.9-1.7)
 2000 268 (9.7) 77 (9.3) 1.2 (0.9-1.6)
 2001 238 (8.6) 90 (10.9) 1.4 (1.1-1.9)
 2002 265 (9.5) 73 (8.9) 1.0 (0.8-1.4)
 2003 276 (9.9) 77 (9.3) 1.2 (0.9-1.6)
 2004 264 (9.5) 106 (12.9) 1.4 (1.1-1.9)
 2005 331 (11.9) 69 (8.4) 0.9 (0.6-1.2)
 2006 322 (11.6) 82 (9.9) 0.9 (0.7-1.2)
 2007 333 (12.0) 79 (9.6) Reference
Bold results indicate p-value <0.05
a
Private insurance included employer-based insurance (including Tricare). Public insurance included Medicare, Medicaid, Veteran’s 
Administration insurance, and other state and local government health insurance in Florida, such as KidCare.
b
CCHD identified by ICD-9-CM codes: HLHS: 746.7, AI/A: 747.11, 747.22; COA: 747.10; DORV: 745.11; d-TGA: 745.10; EA: 746.2; PA: 
746.01; SV: 745.3; TA: 745.0; TAPVC: 747.41; TOF: 745.2; TRA: 746.1.
c
Primary targets for pulse oximetry screening.1,14,15
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Table 2









 ≤ 24 1.0 (0.9-1.2)
 25-34 Reference
 ≥35 1.0 (0.9-1.0)
Mother’s race / ethnicity
 White, non-Hispanic Reference
 Black, non-Hispanic 1.1 (0.9-1.2)
 Hispanic 1.0 (0.8-1.2)
 Asian / Pacific Islander and American Indian / Alaskan 1.3 (0.8-2.0)
Mother’s education
 Less than high school graduate 1.0 (0.8-1.2)
 High school graduate or equivalent 1.2 (1.0-1.4)
 College or university (some or graduate) Reference
Mother’s nativity: foreign-born 0.8 (0.7-1.0)
Principal healthcare payer type on birth hospitalization record
b
 Private Reference
 Public 1.0 (0.9-1.2)
 Self-Insured/Uninsured 1.2 (0.9-1.6)
Birth hospital nursery level
 I 1.9 (1.6-2.2)
 II 1.5 (1.3-1.7)
 III Reference
Infant
Sex, female 1.0 (0.9-1.1)
Preterm or very preterm birth (20-36 weeks) 0.9 (0.7-1.0)
Non-cardiac congenital anomaly 0.9 (0.8-1.1)
Plurality: multiple gestation 0.8 (0.5-1.3)
Critical congenital heart disease type (CCHD)
c,d
Single condition
 Hypoplastic left heart syndrome (HLHS)
d
Reference
 Aortic interruption/atresia/hypoplasia (AI/A) 2.2 (1.4-3.4)
 Coarctation/hypoplasia of aortic arch (COA) 2.9 (2.1-4.0)
 Double-outlet right ventricle (DORV) 2.5 (1.7-3.8)



















 Dextro-transposition of the great arteries (d-TGA)
d
0.8 (0.5-1.2)
 Ebstein anomaly (EA) 0.8 (0.6-1.7)
 Pulmonary atresia (PA)
d
1.7 (1.1-2.7)
 Single ventricle (SV) 2.2 (1.1-4.1)
 Truncus arteriosus (TA)
d
2.5 (1.7-3.8)
 Total anomalous pulmonary venous connection (TAPVC)
d
2.7 (1.8-4.0)
 Tetralogy of Fallot (TOF)
d
1.9 (1.4-2.6)




 1998 1.0 (0.8-1.4)
 1999 1.2 (0.9-1.6)
 2000 1.2 (1.0-1.6)
 2001 1.4 (1.1-1.8)
 2002 1.1 (0.8-1.4)
 2003 1.2 (0.9-1.5)
 2004 1.4 (1.1-1.8)
 2005 0.9 (0.7-1.2)
 2006 0.9 (0.7-1.1)
 2007 Reference
Bold results indicate p-value <0.05
a
Adjusted models controlled for all characteristics listed in the table. The results shown here are for the multivariable model which examined the 
effect of CCHD type for infants with a single CCHD, and therefore excludes infants with multiple CCHDs.
b
Private insurance included employer-based insurance (including Tricare). Public insurance included Medicare, Medicaid, Veteran’s 
Administration insurance, and other state and local government insurance in Florida, such as KidCare.
c
CCHD identified by ICD-9-CM codes: HLHS: 746.7, AI/A: 747.11, 747.22; COA: 747.10; DORV: 745.11; d-TGA: 745.10; EA: 746.2; PA: 
746.01; SV: 745.3; TA: 745.0; TAPVC: 747.41; TOF: 745.2; TRA: 746.1.
d
Primary targets for pulse oximetry screening.114,15
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